Back to Search
Start Over
Supplementary Figure 1 from Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Figure S1. Trametinib sensitivity of EGFR mutant NSCLC cell lines and inhibition of ERK dependent genes. (A) Inhibition of ERK1/2 was assessed in each cell line after 8 hours of treatment followed by immunoblot for total and phosphorylated ERK1/2. Hsp90 was used as a loading control. (B) The viability of PC9, HCC4006, HCC2279 and HCC2935 cells was assessed after 72 hours. (C) PC9 GR4 (EGFR Del746_A750/T790M) cells were treated with DMSO (Media), 100 nM WZ4002, 30 nM trametinib or a combination thereof for 8 hours or (D) 24 hours and ERK1/2 dependent gene transcription was assessed by quantitative PCR, asterisk, p < 0.05 by one-tailed t-test.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....ac2bf0e9125a40905449894ad8a77dc9
- Full Text :
- https://doi.org/10.1158/2159-8290.22531614.v1